|dc.description.abstract||lonophore supplements are widely used in the ration of fattening beef cattle,
especially in the United States. Studies have indicated benefits in terms of a
faster growth rate and live weight gain and a reduction in feed intake in beef
cattle fed either monensin or lasalocid. In recent years interest has been
growing on the possible use of ionophores in dairy cattle. This is because
changes in rumen metabolism associated with ionophores could increase milk
production in lactating ruminants and/or reduce health and reproductive
Two experiments were conducted with dairy cows at grazing to evaluate the
effects of Bovatec 20 (lasalocid) on milk production and performance in early
and mid-lactation. In Experiment 1 thirty multiparous Friesian cows aged
between three and nine years were assigned to two similar treatment groups
of 15 cows balanced for age, previous lactation production, body weight and
body condition prior to calving. Treatments consisted of no lasalocid (control)
and 400 mg lasalocid per cow per day (drenched twice daily) and the
experiment commenced 7 days postpartum. Milk yield and composition were
measured at weekly intervals and the treatment continued for ten weeks.
Gross energy content of milk was estimated from milk composition. Blood was
sampled by tail venipuncture at weekly intervals during morning milking and
serum harvested. Serum was analyzed for concentrations of non-esterified
fatty acids, B-hydroxybutyrate, glucose, magnesium and calcium.
Reproductive parameters (calving to first oestrus, calving to conception
intervals and the number of services per conception) were calculated from
farm records collected during the experiment.
No differences in milk, milk fat, protein, or lactose yields were observed.
Significant (P<0.01) lasalocid by period interaction was observed for milk fat
yield. Gross energy content in milk did not differ between groups but period
effects were significant (P<O.lO) during weeks 3, 6, 7 and 9. Period by
lasalocid interaction for gross energy content of milk was also significant
(P<0.1 0). Lasalocid treatment did not affect live weight changes of cows in
early lactation. Lasalocid treated cows lost significantly (P<0.05) more
condition than control cows. Plasma concentrations of B-hydroxybutyrate,
non-esterified fatty acids, glucose, magnesium and calcium were unaffected
by lasalocid. Period by lasalocid effects for non esterified fatty acids and for
magnesium were significant (P<0.05 and P<0.10, respectively). Reproductive
parameters were unaffected by lasalocid supplementation.
In Experiment 2 forty-five multiparous Friesian cows in mid-lactation were
divided into three groups using the criteria as in Experiment 1. The groups
were randomly allocated to three treatments. Treatments consisted of a
control group, a group treated with Bovatec 20 (lasalocid) as in Experiment 1,
and a third group treated with Bloatenz (a bloat preventive formulation).
Treatments lasted 10 weeks. Milk yield and composition, live weight and body
condition scores were measured as in Experiment 1. Cows were also scored
for intensity of bloat for two periods each of 7 days.
Treatment with either Bovatec 20 or Bloatenz did not affect milk, fat, protein
or lactose yields of cows in mid-lactation. Period effects for fat yield were
significant (P<0.05). Gross energy content in milk was unaffected by
treatment. Live weight changes were unaffected by treatments but cows
treated with Bovatec 20 and Bloatenz lost less condition compared to control
cows. The pastures used failed to induce bloat and hence there were no data
for this aspect of the study.
It was concluded that feeding lasalocid resulted in only small numerical
increases in milk production in early lactation with no milk production
responses in mid-lactation. Lasalocid had minor negative influence on body
condition in early lactation and a significant positive influence in mid-lactation.||en